MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial

MAIA Biotechnology, Inc.

Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.
Share price set at 120% of 30-day VWAP; minimum share price of $1.74; maximum shares issuable at minimum price: 337,876.
Shares are unregistered, issued under Section 4(a)(2); subject to 19.99% blocker and Exchange Cap.
Proceeds used to fund a multicenter Phase 3 study of THIO sequenced with cemiplimab in advanced NSCLC.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.